This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

milvexian
Medical Information

LIBREXIA ACS Trial

Last Updated: 11/18/2026

SUMMARY

  • LIBREXIA ACS (NCT05754957)1 was an international, randomized, double-blind, placebo-controlled, event-driven phase 3 trial that evaluated the efficacy and safety of milvexian 25 mg added to standard-of-care (SoC) antiplatelet therapy in patients aged ≥18 years after a recent (within 7 days) acute coronary syndrome (ACS; N=14,194).
    • The primary efficacy outcome was the time to first occurrence of the composite of cardiovascular (CV) death, myocardial infarction (MI), or ischemic stroke, and the principal safety outcome was Bleeding Academic Research Consortium (BARC) type 3c or 5 bleeding.
    • The trial was halted for futility after a prespecified interim analysis.
    • After a median follow-up of 12.2 months (interquartile range, 6.28-17.61), the primary endpoint event was reported in 384 (5.4%) patients in the milvexian group and 365 (5.1%) patients in the placebo group (hazard ratio [HR], 1.05;
      95% confidence interval [CI], 0.91-1.21; P=0.50).
    • The rate of BARC type 3c or 5 bleeding was similar between the groups.

BRISTOL MYERS SQUIBB AND JOHNSON & JOHNSON COLLABORATION

Milvexian is an oral investigational factor XIa inhibitor being studied for the prevention of major thrombotic conditions in a worldwide collaboration program between Bristol Myers Squibb and Johnson & Johnson. Milvexian is not currently approved for any use.

To read more about how Johnson & Johnson processes personal data, please visit https://innovativemedicine.jnj.com, select your country or region (in the upper right corner), and then click on Privacy Policy.

To read more about how Bristol Myers Squibb processes personal data, please visit https://www.bms.com, select your country (in the upper right corner), and then click on Privacy Policy.

CLINICAL DATA

LIBREXIA ACS Trial

LIBREXIA ACS1 was an international, randomized, double-blind, placebo-controlled,
event-driven phase 3 trial that evaluated the efficacy and safety of milvexian 25 mg added to SoC antiplatelet therapy among adult patients after a recent (within 7 days) ACS (N=14,194).

Study Design/Methods

  • Key inclusion criteria:
    • Participants aged ≥18 years who experienced an index ACS event within 7 days before randomization, with the ACS event defined as the presence of any of the following:
      • ST-segment elevation MI (STEMI)
      • Type 1 non-ST-segment elevation MI (NSTEMI)
      • Unstable angina with cardiac biomarker positivity
    • Participants must have ≥2 of the following risk factors:
      • Age ≥65 years
      • Diabetes mellitus
      • History of an MI event
      • Multivessel coronary artery disease (CAD)
      • History of coronary-artery bypass graft (CABG) surgery before the index ACS event
      • History of peripheral artery disease (PAD) or cerebrovascular disease
      • Conservative management
      • High-risk angiographic features
  • Key exclusion criteria:
    • Type 2 MI
    • Nonobstructive CAD
    • Need for chronic anticoagulation
    • High bleeding risk
    • Dialysis
    • Advanced liver disease
    • Active cancer
    • Prior ischemic stroke or transient ischemic attack
    • Factor XI deficiency
  • Participants were randomized 1:1 to receive the following:
    • Milvexian 25 mg orally twice daily + SoC antiplatelet therapy (single antiplatelet therapy [SAPT] or dual antiplatelet therapy [DAPT]), or
    • Placebo orally twice daily + SoC antiplatelet therapy (SAPT or DAPT)
  • The primary efficacy outcome was the time to first occurrence of the composite of CV death, MI, or ischemic stroke.
  • The first major secondary efficacy outcome was a composite of CV death, MI, ischemic stroke, major adverse limb event (MALE), or symptomatic venous thromboembolism (VTE).
  • The principal safety endpoint was BARC type 3c or 5 bleeding.

Results

Baseline Characteristics
  • A total of 14,194 participants were included in the intention-to-treat analysis (milvexian=7094; placebo=7100). Baseline characteristics were well balanced between the treatment groups. The baseline characteristics are shown in Table: Selected Baseline Characteristics.

Selected Baseline Characteristics1
Characteristic
Milvexian
(n=7094)

Placebo
(n=7100)

Age, years, mean (SD)
63.1 (10.6)
63.2 (10.5)
   Age ≥65 years, n (%)
3545 (50.0)
3559 (50.1)
Male sex, n (%)
5542 (78.1)
5543 (78.1)
Medical history, n (%)
   Hypertension
5181 (73.0)
5083 (71.6)
   Diabetes
3014 (42.5)
3154 (44.4)
   Prior coronary revascularization
1808 (25.5)
1726 (24.3)
   Prior MI other than the index event
1606 (22.6)
1569 (22.1)
Type of index MI, n (%)
   STEMI
4085 (57.6)
4067 (57.3)
   NSTEMI
2615 (36.9)
2644 (37.2)
   UA with elevated cardiac biomarkers
393 (5.5)
389 (5.5)
PCI performed for index MI, n (%)
6516 (91.9)
6496 (91.5)
Medications at the time of randomization, n (%)
   Aspirin
6884 (97.0)
6893 (97.1)
   P2Y12 inhibitor or other antiplatelet agent
6885 (97.1)
6880 (96.9)
   Statin
6607 (93.1)
6628 (93.4)
Abbreviations: MI, myocardial infarction; NSTEMI, non-ST-segment elevation myocardial infarction; PCI, percutaneous coronary intervention; SD, standard deviation; STEMI, ST-segment elevation myocardial infarction; UA, unstable angina.
Efficacy

The independent data monitoring committee recommended stopping the trial for futility based on the results of a prespecified interim analysis, with the recommendation accepted by the chair of the Program Executive Committee and a small group of unblinded sponsor representatives.

After a median follow-up of 12.2 months (interquartile range, 6.28-17.61), the primary endpoint event was reported in 384 (5.4%) patients in the milvexian group and 365 (5.1%) patients in the placebo group (HR, 1.05; 95% CI, 0.91-1.21; P=0.50). Results were consistent across all prespecified subgroups. The data for efficacy endpoints are listed in Table: Primary and Key Secondary Efficacy Outcomes.


Primary and Key Secondary Efficacy Outcomes1
Outcome
Milvexian
(n=7094)

Placebo
(n=7100)

HR
(95% CI)

n (%)
Event Rate per 100 Person-Years
(95% CI)

n (%)
Event Rate per 100 Person-Years
(95% CI)

Primary outcome
   CV death, MI, or ischemic
   strokea

384
(5.4)

5.60
(5.06-6.19)

365
(5.1)

5.33
(4.81-5.90)

1.05
(0.91-1.21)

      CV death
110
(1.6)

1.54
(1.28-1.86)

112
(1.6)

1.57
(1.30-1.89)

0.98
(0.75-1.28)

      MI
249
(3.5)

3.61
(3.19-4.09)

236
(3.3)

3.43
(3.02-3.89)

1.05
(0.88-1.26)

      Ischemic stroke
60
(0.8)

0.85
(0.66-1.10)

46
(0.6)

0.66
(0.49-0.88)

1.30
(0.89-1.91)

Key secondary outcomes
   CV death, MI, ischemic
   stroke, major adverse
   limb events, or
   symptomatic VTE

402
(5.7)

5.87
(5.32-6.47)

386
(5.4)

5.65
(5.11-6.24)

1.04
(0.90-1.20)

   All-cause mortality, MI,
   and ischemic stroke

430
(6.1)

6.27
(5.70-6.89)

408
(5.7)

5.95
(5.40-6.56)

1.05
(0.92-1.21)

      CV death
110
(1.6)

1.54
(1.28-1.86)

112
(1.6)

1.57
(1.30-1.89)

0.98
(0.75-1.28)

      All-cause mortality
158
(2.2)

2.21
(1.89-2.59)

164
(2.3)

2.30
(1.97-2.68)

0.96
(0.77-1.20)

Abbreviations: CI, confidence interval; CV, cardiovascular; HR, hazard ratio; MI, myocardial infarction; VTE, venous thromboembolism.
a
P=0.50.

Safety

The rates of safety outcomes appeared similar between the groups. Selected safety outcomes are listed in Table: Safety Outcomes.


Safety Outcomes1,a
Outcome
Milvexian
(n=7008)

Placebo
(n=7027)

HR
(95% CI)

n (%)
Event Rate per 100 Person-Years
(95% CI)

n (%)
Event Rate per 100 Person-Years
(95% CI)

Principal safety outcomeb
   BARC 3c and 5 bleedingc
23
(0.3)

0.37
(0.25-0.56)

22
(0.3)

0.36
(0.24-0.54)

1.04
(0.58-1.87)

Key secondary safety outcomes
   BARC bleeding
   (type 3b, 3c, and 5)

62
(0.9)

1.01
(0.79-1.29)

64
(0.9)

1.04
(0.82-1.33)

0.97
(0.68-1.37)

      BARC 3b
40
(0.6)

0.65
(0.48-0.89)

42
(0.6)

0.68
(0.51-0.93)

0.95
(0.62-1.47)

      BARC 3c
14
(0.2)

0.23
(0.13-0.38)

16
(0.2)

0.26
(0.16-0.43)

0.87
(0.43-1.79)

      BARC 5
9
(0.1)

0.15
(0.08-0.28)

6
(0.1)

0.10
(0.04-0.22)

1.50
(0.53-4.21)

   GUSTO severe or
   life-threatening bleeding
   event

27
(0.4)

0.44
(0.30-0.64)

23
(0.3)

0.37
(0.25-0.56)

1.17
(0.67-2.04)

   ISTH major bleeding
105
(1.5)

1.71
(1.41-2.07)

102
(1.5)

1.67
(1.37-2.02)

1.03
(0.78-1.35)

   Non-CABG-related TIMI
   major bleeding

49
(0.7)

0.80
(0.60-1.05)

46
(0.7)

0.75
(0.56-1.00)

1.06
(0.71-1.59)

Adverse events
   Any AE
3656
(52.2)

-
3583
(51.0)

-
-
   AEs leading to treatment
   discontinuation

318
(4.5)

-
333
(4.7)

-
-
   SAEs
819
(11.7)

-
790
(11.2)

-
-
   AE leading to death
71
(1.0)

-
73
(1.0)

-
-
Abbreviations: AE, adverse event; BARC, Bleeding Academic Research Consortium; CABG, coronary-artery bypass graft; CI, confidence interval; GUSTO, Global Use of Strategies to Open Occluded Coronary Arteries; HR, hazard ratio; ISTH, International Society of Thrombosis and Hemostasis; SAE, serious adverse event; TIMI, Thrombolysis in Myocardial Infarction.
aIn the safety analysis, the principal and key secondary safety outcomes included data that were obtained from randomization through 2 days after administration of the last dose of milvexian or placebo. Data regarding AEs were obtained from the time of administration of the first dose of milvexian or placebo through 2 days after administration of the last dose, except for AEs leading to death, which could be recorded at any time after randomization.
bThe BARC scale defines type 2 as clinically overt, actionable bleeding that prompts medical evaluation, minor nonsurgical treatment, or hospitalization; type 3b as overt bleeding with a decrease in hemoglobin of ≥5 g/dL, cardiac tamponade, bleeding requiring surgical control, or bleeding treated with intravenous vasoactive drugs; type 3c as intracranial or intraocular bleeding that compromises vision; and type 5 as fatal bleeding.
cP=0.88.

Literature Search

A literature search of MEDLINE®, EMBASE®, BIOSIS Previews®, DERWENT (and/or other resources, including internal/external databases) was conducted on 18 August 2026.

 

References

1 Gibson CM, Steg PG, Bahit MC, et al. Milvexian with antiplatelet therapy after acute coronary syndrome event. [published online ahead of print August 29, 2026]. N Engl J Med. 2026. doi:10.1056/nejmoa2608717.  

Would you like to clear and leave your conversation? Message history will be lost.